COYA · CIK 0001835022 · operating
Coya Therapeutics is a clinical-stage biotechnology company focused on developing therapies that enhance regulatory T cell (Treg) function. The company's pipeline centers on three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. COYA 302, a biologic combination administered subcutaneously, represents the most advanced candidate and is currently in Phase 2 trials for amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is developing this candidate in collaboration with Dr. Reddy's Laboratories SA.
The pre-clinical pipeline includes COYA 301, a low-dose interleukin-2 product candidate for Alzheimer's disease; COYA 303, combining COYA 301 with a glucagon-like-peptide-1 receptor agonist for inflammatory diseases; and multiple exosome-based candidates (COYA 201, COYA 206, and COYA 101) targeting neurodegenerative, autoimmune, and metabolic diseases.
The company operates with a small footprint of eight full-time employees and is headquartered in Houston, Texas. As a pre-revenue, clinical-stage entity, Coya Therapeutics does not generate material revenue. The company was founded in 2020 and is incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.98 | $-0.98 | -24.1% | |
| 2023 | $-0.79 | $-0.79 | +83.3% | |
| 2022 | $-4.73 | $-4.73 | — |